BCL2 and posterior cortical atrophy: ,12,13,14,16,18 Furthermore, the clinical development of drugs targeting the anti-apoptotic BCL2 family proteins, which include the food and drug administration (FDA) approved BH3 mimetic BCL2 inhibitor venetoclax, and novel strategies utilizing ADC and PROTAC approaches, provide exciting opportunities to target intrinsic apoptosis in PCa.6